1131 related articles for article (PubMed ID: 32376136)
1. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
2. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.
Salgia NJ; Bergerot PG; Maia MC; Dizman N; Hsu J; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
Eur Urol; 2020 Oct; 78(4):498-502. PubMed ID: 32828600
[TBL] [Abstract][Full Text] [Related]
3. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.
Dizman N; Hsu J; Bergerot PG; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
Cancer Med; 2021 Jan; 10(1):79-86. PubMed ID: 33135866
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
6.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
9. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
[TBL] [Abstract][Full Text] [Related]
10. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
Billon E; Chanez B; Rochigneux P; Albiges L; Vicier C; Pignot G; Walz J; Chretien AS; Gravis G; Olive D
Front Immunol; 2021; 12():670827. PubMed ID: 33959132
[TBL] [Abstract][Full Text] [Related]
11. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
12.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
13. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
[TBL] [Abstract][Full Text] [Related]
14. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Betancor YZ; Ferreiro-Pantín M; Anido-Herranz U; Fuentes-Losada M; León-Mateos L; García-Acuña SM; Vaamonde-Rodríguez V; García-Pinel B; Cebey-López V; Villaverde-Viaño R; Lombardía-Rodríguez H; Kotrulev M; Fernández-Díaz N; Gomez-Tourino I; Fernández-Baltar C; García-González J; Tubio JMC; López-López R; Ruiz-Bañobre J
Front Immunol; 2024; 15():1374728. PubMed ID: 38660294
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
17. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
18. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Zhang F; Ferrero M; Dong N; D'Auria G; Reyes-Prieto M; Herreros-Pomares A; Calabuig-Fariñas S; Duréndez E; Aparisi F; Blasco A; García C; Camps C; Jantus-Lewintre E; Sirera R
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34063829
[TBL] [Abstract][Full Text] [Related]
20. Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Uehara K; Tanoue K; Yamaguchi K; Ohmura H; Ito M; Matsushita Y; Tsuchihashi K; Tamura S; Shimokawa H; Isobe T; Shibata Y; Ariyama H; Tanaka R; Kusaba H; Yamamoto H; Oda Y; Akashi K; Baba E
Cancer Immunol Immunother; 2023 Nov; 72(11):3543-3558. PubMed ID: 37550428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
